The FDA has authorized the Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and therapeutic agent MNPR-101-Lu, allowing patients with advanced solid tumors access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback